Markets closed

Revolution Medicines, Inc.

RVMD · Nasdaq

Analyst Consensus

Buy

13 analysts

$206

Current

—

Low

$248

Average

—

High

Average target implies +20.65% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 13 analysts, with a mean target of $210; the low and high targets are unavailable, so the target cluster and its full width cannot be measured. The evidence does not identify the most or least bullish analyst. It also does not document a dated revision during the past week. Other pages show incompatible figures, including Simply Wall St’s target moving from $174 to $181, TipRanks’ $182.78 average, and Zacks’ $62-to-$87 range, but the analyst populations and dates are not reconciled. Accordingly, the substantive disagreement appears to concern valuation of an unprofitable, pre-revenue oncology pipeline, but its exact analyst-level dimensions are not supplied.

Rating Actions

No individual rating actions have been captured for RVMDyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

GOLDMAN SACHS

GUGGENHEIM SEC.

H C WAINWRIGHT

JP MORGAN SECUR

LEERINK PARTNRS

NEEDHAM & CO.

OPPENHEIMER HLD

RAYMOND JAMES

STIFEL NICOLAUS

TD COWEN

UBS

WEDBUSH SECURIT

Symbol: RVMD
Type: Stock
Sector: Health Care
Industry: Biological Products, (No Diagnostic Substances)
Exchange: Nasdaq

Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.

Key Issues

Bullish view

Revolution Medicines has a promising cancer drug in development, and the stock has attracted favorable coverage and a 13-analyst Buy consensus. Those signals support the view that future clinical and commercial potential can underpin the valuation.

Bearish view

The company reports no revenue and lost $1.1 billion in FY2025. Until the development program produces commercial evidence, the valuation rests on an unmarketed asset and carries substantial execution risk.

Analyst Consensus

See all

Buy

13 analysts

$206

Current

—

Low

$248

Average

—

High

Average target implies +20.65% versus the current price.

Earnings History

BeatMissNo estimate

Revolution Medicines, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers